Merck’s $6.7B Terns buy is less about leukemia than life after Keytruda.

When one drug drives nearly half of revenue, M&A becomes a way to buy time before the patent cliff.

#Biotech #Pharma #Merck #Oncology #PatentCliff #BiotechM&A #TechNews #BioTechNews

Curative Biotechnology Executes 1-for-150 Reverse Split Curative Biotechnology announced a 1-for-150 reverse split on Mar 23, 2026, cutting shares by ~99.33% and prompting close monitoring of 8-Ks, option adjustments and potential financings.

Curative Biotechnology Executes 1-for-150 Reverse Split: Curative Biotechnology announced a 1-for-150 reverse split on Mar 23, 2026, cutting shares by ~99.33% and prompting close monitoring of 8-Ks, option… 👈 Read full analysis #CurativeBiotechnology #ReverseSplit #BiotechNews #StockMarket #Finance

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation - Biotech Industry Examiner The rovadicitinib deal is about more than one blood-cancer and transplant asset. It is another sign that global pharma is no longer treating China mainly as a

China is no longer just a biotech market. It is increasingly a source of licensable innovation for global pharma.

Sanofi’s up-to-$1.53B rovadicitinib deal is the latest signal — and part of a much bigger shift in where drug innovation begins.

#Biotech #Pharma #ChinaBiotech #BiotechNews #TechNews

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug AdministrationO...

$ATAI surges on Q4 2025 earnings beat, BPL-003 on track for Phase 3 in Q2 2026 for treatment-resistant depression
#ATAIStock #MentalHealthInvesting #BiotechNews

https://a777.lt/VbxyFj

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipa

$JADE Rises: Jade Biosciences to Release JADE101 Phase 1 Interim Data in Q2 2026, Phase 2 Trials to Follow
Jade Biosciences to report JADE101 interim data in Q2 2026, starts Phase 2 trials mid-2026
#BiotechNews #JadeBiosciences #InvestInHealthcare

https://a777.lt/XhSo5V

ONCOassist Universal Link Opening ONCOassist app...

🔷 Based on Phase 3 VERIFY data, if approved, Rusfertide could become a first-in-class therapy, offering a novel treatment approach for patients requiring improved hematocrit control.

🔗 Read more: bit.ly/ONCOnews03-M...

#ONCOnews #OncoAlert #OncEd #BiotechNews #PharmaNews #Oncology #Hematology

Gilead’s $7.8B Arcellx buy: when a partnership turns into an “option exercise” in CAR-T - Biotech Industry Examiner On February 23, 2026, Gilead agreed to acquire Arcellx in a deal valued at up to $7.8 billion—a headline number that’s easy to file under “Big Pharma goes

Gilead’s $7.8B Arcellx buy isn’t just M&A. It’s an “option exercise” on CAR-T: pay up to own the flywheel—manufacturing, label expansion, and the economics of scale.

biotech.industryexaminer.com/gilead-arcel...

#Biotech #CellTherapy #CART #Oncology #M&A #TechNews #BiotechNews #MultipleMyeloma

Technically Oversold with Support Solid Patents & A Heavyweight Board: Is This Stock Set to Soar? Arch Biopartners Inc (ARCH:TSXV; ACHFF:OTCQB) is a therapeutic biotech company focused on developing novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The companys...

📰 Streetwise Reports featured Arch Biopartners in a contributed technical analyst opinion discussing the company’s kidney-focused pipeline and recent public disclosures.

🔗 Read the full report here: www.streetwisereports.com/article/2026...

#ArchNews #BiotechNews

Lilly’s $2.4bn in-vivo CAR-T bet: can RNA turn cell therapy into a scalable drug? - Biotech Industry Examiner On February 9, Eli Lilly agreed to buy Orna Therapeutics for up to $2.4bn in cash, betting that one of biotech’s most powerful treatment ideas — CAR-T cell

CAR-T works. But it’s bespoke: collect cells, engineer, ship back — often 3–6 weeks. Lilly’s up-to-$2.4bn Orna deal bets on in-vivo CAR-T (circular RNA + LNPs) to make an autoimmune “immune reset” scalable. biotech.industryexaminer.com/lilly-orna-i...
#Biotech #CART #EliLilly #TechNews #BiotechNews

New global partnership aims to turn PepLib’s peptide tech into therapies that could reshape treatment and longevity.

vist.ly/4qxqu

#longevity #PeptideTherapeutics #DrugDiscovery #BiotechNews #PharmaInnovation #RAndD

🧵 [3/6]
Sec, Tat, or ABC? Understand the export pathways that make or break protein production in bacteria.

🌐 #MolecularBiology #GeneticEngineering #BiotechNews
@alisyngayle.bsky.social @science-george.bsky.social @manjeet786.bsky.social @georgeradics.bsky.social @ustinoff.bsky.social

Investors show appetite for Veradermics’ extended-release oral minoxidil therapy, with Phase 3 trial currently underway.

vist.ly/4qi87

#longevity #BiotechNews #HairLossResearch #SkinHealth #LifeSciences

#GenerateBiomedicines has filed for an #IPO on the #Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly #asthma drug. #lifesciences #biotechnews #respiratoryhealth pharmaphorum.com/news/flagshi...

Preclinical results spotlight a new AI-driven approach to obesity, one tied less to appetite alone and more to long-term metabolic health.

longevity.technology/news/insilic...

#longevity #aiinmedicine #drugdiscovery #obesityresearch #digitalhealth #biotechnews

PMD trial ties functional measures with NAD⁺ and redox biomarkers, offering a pragmatic view of mitochondrial modulation.

longevity.technology/news/mitocho...

#longevity #mitochondria #clinicaltrials #neurodegeneration #biotechnews #translationalmedicine

As shares rebound, investors are weighing whether the biotech’s cancer pipeline could define its next chapter.

longevity.technology/news/biontec...

#longevity #biotechinvesting #mRNA #cancerresearch #biotechnews #futuremedicine

New research suggests diabetes drugs could shield retinal cells and help prevent diabetes-related vision loss.

longevity.technology/news/glp-1-w...

#longevity #GLP1 #metabolichealth #diabetes #visionhealth #retina #healthspan #preventivehealth #weightloss #biotechnews #medicine #agingwell

New fast-track voucher program hits roadblocks, affecting Eli Lilly and Sanofi’s medicines among others.

longevity.technology/news/fda-rev...

#longevity #FDA #biotechnews #pharmanews #weightlossdrug #metabolichealth #GLP1 #drugdevelopment #healthpolicy #clinicaltrials

Early results show weight loss, stronger mobility and preserved muscle in older adults, an uncommon combination in obesity and aging research.

longevity.technology/news/immunis...

#longevity #sarcopenia #musclehealth #clinicaltrials #biotechnews #healthspan #mobility #agingwell

Investigational COYA 302 Shows Feasibility, Preliminary Efficacy in Small Trial of Frontotemporal Dementia | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Coya Therapeutics reveals promising results for COYA 302, a potential treatment for frontotemporal dementia, showing cognitive stability and Treg enhancement.

🧠💉 #FTD research update
Investigational COYA 302 showed stable cognition over 6 months in a small FTD trial, alongside rapid & sustained Treg enhancement. FDA has now accepted the IND. Early but promising

🔗 ➡️ www.neurologylive.com/view/investi...
#Neurology #ClinicalTrials #BiotechNews #FDA

Health Canada approves Rybelsus, the first oral GLP-1 pill to lower cardiovascular risk in adults with Type 2 diabetes.

longevity.technology/news/canada-...

#longevity #GLP1 #diabetes #cardiometabolic #hearthealth #metabolichealth #obesitycare #digitalhealth #biotechnews

With its immune-restoring TRIIM platform in the XPRIZE Healthspan semifinals, the company says the body ‘still remembers how to be young’.

longevity.technology/news/interve...

#longevity #immunology #thymus #immunerejuvenation #inflammaging #healthspan #agingwell #biotechnews

The approval marks a milestone for GLP-1 drugs, expanding access beyond injections as Novo Nordisk prepares for a competitive obesity market.

longevity.technology/news/wegovys...

#longevity #GLP1 #ObesityResearch #MetabolicHealth #BiotechNews #FDAApproval #NovoNordisk

Regenerative medicine firm says new capital gives it breathing room to sharpen its placenta-derived tech aimed at aging and chronic disease.

longevity.technology/news/celular...

#longevity #regenerativemedicine #celltherapy #biotechnews #healthspan #aginginnovation

Thryv Therapeutics is heading to SF for the 44th JPM Conference! We’ll be sharing updates on our SGK1 inhibitor programs and upcoming milestones.

Schedule a meeting: admin@thryvtrx.com

#JPM2026 #BiotechNews #LifeSciences #CardiacHealth #SGK1

From Cow-Free Dairy to Human Milk 2.0: Biotechs Race to Brew Breast Milk Proteins - Biotech Industry Examiner The first wave of “milk without cows” promised more sustainable cheese and ice cream. The next wave is far more ambitious – and politically fraught. Start-ups

#Biotechs are moving beyond cow-free dairy into Human Milk 2.0 – brewing breast milk proteins like lactoferrin in steel tanks for the US$90bn formula market. Science, economics, ethics all collide in our new explainer
biotech.industryexaminer.com/cow-free-dai...
#HumanMilk2_0 #BiotechNews #TechNews

#killKillKill #healthNews #legalNews #GMO #defectiveProduct #biotech #biotechHealth #scienceBiotech #biotech_and_pharmaceuticals #biotechNews #backyardMassacre #oncology #glyphosate #consumerProtection #productLiability #releaseUnredactedMRI [2/3]

Daily Updates 11/24/25

Piper Sandler reiterates Buy on $NXTC, $15 PT after $21.5M raise and pipeline updates. #BiotechNews

www.biopharmcatalyst.com/news/2025/pa...

Daily Updates 09/26/25

$LEXX to sell 2.67M shares at $1.50/share in a direct offering. #BiotechNews $PEPG $SPRC $EVAX $PSTV $IMRX $RENB $VINC $LPTX $ZYBT $CURX

www.biopharmcatalyst.com/news/2025/le...

Sanofi juices up biotech investment arm with $625M cash infusion Sanofi is bestowing $625 million on its investment arm Sanofi Ventures, seeking to take advantage of a biotech landscape that is light on capital yet still heavy on scientific innovation. | Sanofi is ...

🚨 Fierce: “Sanofi juices up biotech investment arm with $625M” (bit.ly/sanofi-625m-cash-infusion).

Arch is a therapeutic biotech with two Phase II programs for AKI and preclinical IP advancing kidney therapeutics in CKD.

🔬 archbiopartners.com/our-science/

#AKI #CKD #BiotechNews #NephSky